Regulation and signaling of the LIM domain kinases

G Casanova‐Sepúlveda, TJ Boggon - BioEssays, 2025 - Wiley Online Library
The LIM domain kinases (LIMKs) are important actin cytoskeleton regulators. These
proteins, LIMK1 and LIMK2, are nodes downstream of Rho GTPases and are the key …

LIM kinases in cardiovascular health and disease

OM Lateef, C Foote, G Power… - Frontiers in …, 2024 - frontiersin.org
The Lim Kinase (LIMK) family of serine/threonine kinases is comprised of LIMK1 and LIMK2,
which are central regulators of cytoskeletal dynamics via their well-characterized roles in …

[HTML][HTML] Exosomal mRNA Signatures as Predictive Biomarkers for Risk and Age of Onset in Alzheimer's Disease

DA Bolívar, MI Mosquera-Heredia, OM Vidal… - International Journal of …, 2024 - mdpi.com
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by progressive
cognitive decline and memory loss. While the precise causes of AD remain unclear …

Systematic identification and characterization of exon–intron circRNAs

Y Zhong, Y Yang, X Wang, B Ren, X Wang… - Genome …, 2024 - genome.cshlp.org
Exon–intron circRNAs (EIciRNAs) are a circRNA subclass with retained introns. Global
features of EIciRNAs remain largely unexplored, mainly owing to the lack of bioinformatic …

Discovery of MDI-114215: A potent and selective LIMK inhibitor to treat fragile X syndrome

AG Baldwin, DW Foley, R Collins, H Lee… - Journal of Medicinal …, 2024 - ACS Publications
LIMKs are serine/threonine and tyrosine kinases responsible for controlling cytoskeletal
dynamics as key regulators of actin stability, ensuring synaptic health through normal …

Decoding the tumour-modulatory roles of LIMK2

ZX Chong, WY Ho, SK Yeap - Life Sciences, 2024 - Elsevier
Abstract LIM domains kinase 2 (LIMK2) is a 72 kDa protein that regulates actin and
cytoskeleton reorganization. Once phosphorylated by its upstream activator (ROCK1) …

[HTML][HTML] Tetrahydropyridine LIMK inhibitors: Structure activity studies and biological characterization

A Champiré, R Berabez, A Braka, A Cosson… - European Journal of …, 2024 - Elsevier
Abstract LIM Kinases, LIMK1 and LIMK2, have become promising targets for the
development of inhibitors with potential application for the treatment of several major …

[HTML][HTML] Targeting MAD2B as a strategy for ischemic stroke therapy

L Zhang, H Cui, W Hu, X Meng, C Zhang - Journal of Advanced Research, 2024 - Elsevier
Introduction Post-stroke cognitive impairment is one of the major causes of disability due to
cerebral ischemia. MAD2B is an inhibitor of Cdh1/APC, and loss of Cdh1/APC function in …

Practical Three-Component Regioselective Synthesis of Drug-Like 3-Aryl(or heteroaryl)-5,6-dihydrobenzo[h]cinnolines as Potential Non-Covalent Multi-Targeting …

H Mousavi, M Rimaz, B Zeynizadeh - ACS Chemical …, 2024 - ACS Publications
Neurodegenerative diseases (NDs) are one of the prominent health challenges facing
contemporary society, and many efforts have been made to overcome and (or) control it. In …

[HTML][HTML] Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence

J Zhang, Y Ma - Biomedicine & Pharmacotherapy, 2024 - Elsevier
Lung cancer is a prevalent malignant tumor and a leading cause of cancer-related fatalities
globally. However, current treatments all have limitations. Therefore, there is an urgent need …